BDR Pharma buys majority stake in Acme oral care business
In short
BDR Pharma has bought a majority stake in Acme Formulation’s oral care business. Sources close to the deal put the value at about ₹2,370 crore, or $250 million.
The move gives BDR Pharma a bigger presence in oral care. The source gives no further deal details.
What the reporting says
BDR Pharma bought a majority stake in Acme Formulation’s oral care business, according to sources close to the deal. The transaction was valued at about ₹2,370 crore, or $250 million.
Why it matters
BDR Pharma has acquired a majority stake in Acme Formulation’s oral care business in a deal valued at about ₹2,370 crore, or $250 million, according to sources close to the transaction. The reported purchase points to consolidation in the oral care segment and could expand BDR Pharma’s product footprint.